An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...
Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...
This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...
There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced that Roche (SIX: RO, ...
NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced results of a well ...
Osaka, Japan - A research team at The University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene ...
Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. This partnership brings together GENEWIZ's industry-leading ...
HOPEWELL, N.J., Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced the launch of its cGMP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback